Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data.

TİGEN M. K., Ozdil M. H., Cincin A., Gurel E., SÜNBÜL M., Sahin A., ...Daha Fazla

Anatolian journal of cardiology, cilt.25, sa.10, ss.699-705, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 10
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5152/anatoljcardiol.2021.27974
  • Dergi Adı: Anatolian journal of cardiology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.699-705
  • Anahtar Kelimeler: acute coronary syndrome, bleeding, clopidogrel, prasugrel, ticagrelor, tirofiban, ACUTE CORONARY SYNDROMES, GLYCOPROTEIN IIB/IIIA INHIBITOR, PLATELET INHIBITION, ANTIPLATELET, EFFICACY, OUTCOMES, SAFETY, INTERVENTION, METAANALYSIS, CLOPIDOGREL
  • Marmara Üniversitesi Adresli: Evet

Özet

Objective: Combination of dual antiplatelet therapy (DAPT) with glycoprotein (GP) IIb/IIIa inhibitors can increase bleeding risk. In this study, we aimed to investigate bleeding complications of different DAPTs with concomitant tirofiban use in patients with acute coronary syndrome (ACS).